Enhanc3D Genomics Ltd Revenue and Competitors

Cambridge, Cambridge

Location

#5965

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Enhanc3D Genomics Ltd's estimated annual revenue is currently $2.6M per year.(i)
  • Enhanc3D Genomics Ltd's estimated revenue per employee is $88,190

Employee Data

  • Enhanc3D Genomics Ltd has 29 Employees.(i)
  • Enhanc3D Genomics Ltd grew their employee count by 4% last year.

Enhanc3D Genomics Ltd's People

NameTitleEmail/Phone
1
FounderReveal Email/Phone
2
Co-founderReveal Email/Phone
3
VP Operations & Chief StaffReveal Email/Phone
4
Chief Technology OfficerReveal Email/Phone
5
HR ManagerReveal Email/Phone
6
Member the Board Strategic AdvisorsReveal Email/Phone
7
Principal ScientistReveal Email/Phone
8
ScientistReveal Email/Phone
9
Lead ScientistReveal Email/Phone
10
Senior Principal ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.8M1344%N/AN/A
#2
$2.7M3546%N/AN/A
#3
$0.9M1318%N/AN/A
#4
$0.8M1011%N/AN/A
#5
$3.6M4413%$15MN/A
#6
$2.4M3119%$10MN/A
#7
$2.9M3513%$16MN/A
#8
$2.6M294%N/AN/A
Add Company

What Is Enhanc3D Genomics Ltd?

At Enhanc3D Genomics we are creating new applications to improve human healthcare. Our disruptive technology profiles 3D genome folding at high resolution for all genes and their enhancers simultaneously, and thus links gene enhancers and non-coding genetic variants to their target genes to unlock their potential for therapeutic discovery. Enhanc3D Genomics is a spinout company from Babraham Institute (Cambridge, UK), founded by academic scientists who are leaders in the fields of regulatory genomics and chromosomal architecture. Enhanc3D Genomics is a privately held company headquartered in Cambridge, UK.

keywords:N/A

N/A

Total Funding

29

Number of Employees

$2.6M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M2938%$35M
#2
$2.9M29N/AN/A
#3
$300M29-9%$63.7M
#4
$9.1M29-19%N/A
#5
$4.5M297%N/A